Panbela Therapeutics (OTCMKTS:PBLA) & Virpax Pharmaceuticals (NASDAQ:VRPX) Critical Contrast

Valuation & Earnings

This table compares Panbela Therapeutics and Virpax Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Panbela Therapeutics	N/A	N/A	-$25.26 million	($71.13)	0.00
Virpax Pharmaceuticals	N/A	N/A	-$15.19 million	($123.25)	0.00

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

4.4% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 0.0% of Panbela Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Panbela Therapeutics has a beta of 42.31, suggesting that its share price is 4,131% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

Profitability

This table compares Panbela Therapeutics and Virpax Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Panbela Therapeutics	N/A	N/A	N/A
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

Summary

Panbela Therapeutics beats Virpax Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Panbela Therapeutics

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.